Morgan Lewis is serving as lead US antitrust counsel to Pfizer in its proposed combination with Allergan, which will establish a new global biopharmaceutical leader.
The Morgan Lewis team is led by partners Scott Stempel and Harry Robins. Support is provided by partner Clay Everett and associates David Brenneman, Martin d’Halluin, Katie Glynn, and Maria Luisa Di Lauro.
When completed, the transaction will be the largest pharmaceutical industry M &A transaction in history and among the largest M &A transactions of any type. Including this deal, the Morgan Lewis antitrust team has worked on three of the seven largest pharmaceutical transactions ever.
Full content: Pfizer
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
WhatsApp Co-Founder Undermines Antitrust Allegations Against Meta in Court Testimony
May 21, 2025 by
CPI
OpenAI Acquires Jony Ive’s io for $6.4B to Pioneer Post-Smartphone Devices
May 21, 2025 by
CPI
Dior Commits €2 Million to Labor Initiatives in Italian Antitrust Settlement
May 21, 2025 by
CPI
Indonesia’s Antitrust Watchdog Probes Potential Risks of Grab-GoTo Merger
May 21, 2025 by
CPI
Live Nation Taps Trump Ally Richard Grenell Amid DOJ Lawsuit
May 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros